Progesterone levels on hCG trigger day and neonatal outcomes in fresh embryo transfers: a retrospective threshold analysis of GnRH antagonist versus agonist long protocols.
Jing Wu, Hengde Zhang, Jianlei Huang, Li Hai, Xinxin Liang, Dan Liu, Jing Zhou, Xuan Li, Yuping He, Xiaohong Wang
{"title":"Progesterone levels on hCG trigger day and neonatal outcomes in fresh embryo transfers: a retrospective threshold analysis of GnRH antagonist versus agonist long protocols.","authors":"Jing Wu, Hengde Zhang, Jianlei Huang, Li Hai, Xinxin Liang, Dan Liu, Jing Zhou, Xuan Li, Yuping He, Xiaohong Wang","doi":"10.3389/fendo.2026.1982427","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elevated progesterone levels on the day of human chorionic gonadotropin (hCG) trigger are known to adversely affect pregnancy outcomes in fresh embryo transfer (fET) cycles, but their impact on neonatal outcomes remains poorly understood. This study aimed to investigate the association between progesterone levels on hCG trigger day and neonatal outcomes, and to explore the progesterone threshold, so as to provide reference for clinical decision-making.</p><p><strong>Methods: </strong>This retrospective cohort study included 2, 201 patients who achieved singleton live births following fET between April 1, 2021 and December 31, 2024. All patients were ≤ 42 years of age and underwent either a GnRH antagonist protocol or an agonist long protocol. A multivariable regression analysis was performed to detect the relationship between progesterone level and neonatal outcomes. Smooth curve fitting and threshold effect analysis were used to evaluate the cutoff value of progesterone level.</p><p><strong>Results: </strong>In the overall population, higher progesterone levels were significantly associated with increased risks of preterm delivery (PTD) (adjusted OR: 1.89, 95% CI: 1.03 to 3.47, P = 0.0399) and low birthweight (LBW) (adjusted OR: 2.67, 95% CI: 1.14 to 6.24, P = 0.0231). These associations were observed only in the GnRH antagonist protocol, particularly with progesterone ≥ 1.0 ng/mL significantly elevating the risks of PTD (adjusted OR: 4.54, 95% CI: 2.16 to 9.56, P = 0.0021) and LBW (adjusted OR: 4.16, 95% CI: 1.15 to 15.07, P = 0.0378). Threshold analysis further identified progesterone > 0.90 ng/mL as the inflection point for PTD (adjusted OR: 6.60, 95% CI: 2.52 to 14.56, P = 0.0131) and progesterone > 0.98 ng/mL for LBW (adjusted OR: 7.50, 95% CI: 3.71 to 15.87, P = 0.0038) in antagonist cycles. No such associations were found in the GnRH agonist long protocol.</p><p><strong>Conclusions: </strong>Our findings suggest that in GnRH antagonist cycles, a serum progesterone level exceeding 0.90 ng/mL on hCG trigger day may serve as an independent predictor of an increased risk of PTD in singletons born after fET. These results highlight the need for enhanced perinatal surveillance in this population, and call for further validation in larger prospective multicenter studies.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"17 ","pages":"1982427"},"PeriodicalIF":5.7000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682976/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2026.1982427","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Elevated progesterone levels on the day of human chorionic gonadotropin (hCG) trigger are known to adversely affect pregnancy outcomes in fresh embryo transfer (fET) cycles, but their impact on neonatal outcomes remains poorly understood. This study aimed to investigate the association between progesterone levels on hCG trigger day and neonatal outcomes, and to explore the progesterone threshold, so as to provide reference for clinical decision-making.
Methods: This retrospective cohort study included 2, 201 patients who achieved singleton live births following fET between April 1, 2021 and December 31, 2024. All patients were ≤ 42 years of age and underwent either a GnRH antagonist protocol or an agonist long protocol. A multivariable regression analysis was performed to detect the relationship between progesterone level and neonatal outcomes. Smooth curve fitting and threshold effect analysis were used to evaluate the cutoff value of progesterone level.
Results: In the overall population, higher progesterone levels were significantly associated with increased risks of preterm delivery (PTD) (adjusted OR: 1.89, 95% CI: 1.03 to 3.47, P = 0.0399) and low birthweight (LBW) (adjusted OR: 2.67, 95% CI: 1.14 to 6.24, P = 0.0231). These associations were observed only in the GnRH antagonist protocol, particularly with progesterone ≥ 1.0 ng/mL significantly elevating the risks of PTD (adjusted OR: 4.54, 95% CI: 2.16 to 9.56, P = 0.0021) and LBW (adjusted OR: 4.16, 95% CI: 1.15 to 15.07, P = 0.0378). Threshold analysis further identified progesterone > 0.90 ng/mL as the inflection point for PTD (adjusted OR: 6.60, 95% CI: 2.52 to 14.56, P = 0.0131) and progesterone > 0.98 ng/mL for LBW (adjusted OR: 7.50, 95% CI: 3.71 to 15.87, P = 0.0038) in antagonist cycles. No such associations were found in the GnRH agonist long protocol.
Conclusions: Our findings suggest that in GnRH antagonist cycles, a serum progesterone level exceeding 0.90 ng/mL on hCG trigger day may serve as an independent predictor of an increased risk of PTD in singletons born after fET. These results highlight the need for enhanced perinatal surveillance in this population, and call for further validation in larger prospective multicenter studies.
期刊介绍:
Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series.
In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology.
Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.